FOR HEALTHCARE PROFESSIONALS

LISRAYA™ (brepocitinib)

my compass support

Here for You, Your Patients, and Your Team

Important Safety Information

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS

Indications and Usage

LISRAYA (brepocitinib) is indicated for the treatment of adults with dermatomyositis (DM).

Limitations of Use

Not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.

Warnings and Precautions:

Serious infections. Patients treated with LISRAYA are at increased risk of developing serious bacterial, fungal, viral, and opportunistic infections that may lead to hospitalization or death.

See full Prescribing Information including Boxed Warning.

About My Compass Support

My Compass Support is a dedicated program that serves patients who are prescribed LISRAYA as well as their healthcare providers. We will work with you and your team to help your patients throughout their treatment journey.

Support includes:

- **Patient Access Liaison (PAL)**—a dedicated, single point of contact for your patients and your team on all topics related to LISRAYA access
- **Benefits & Authorization**—including benefits investigation, detailed authorization requirements, and submission support
- **Bridge Program**—helping your patients avoid delays in treatment if an authorization request is denied
- **Cost Assistance**—patients may be able to pay as little as $0* a month for LISRAYA
- **Specialty Pharmacy Coordination**—helping your patients receive their monthly shipments of LISRAYA seamlessly

* See My Compass Support Copay Savings Program Terms & Conditions on next page.

Important Safety Information (continued)

Reported infections with use of Janus kinase (JAK) inhibitors, including LISRAYA:

- Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Evaluate and test patients for latent and active TB infection prior to and during LISRAYA treatment. If positive, treat for TB. Monitor all patients for active TB during treatment including patients who tested negative for a latent TB infection prior to LISRAYA treatment.
- Invasive fungal infections. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
- Bacterial, viral (including herpes zoster), and other infections due to opportunistic pathogens.

LISRAYA™ (brepocitinib)

How We Support Your Patients

A dedicated Patient Access Liaison (PAL) provides ongoing, personalized support for your patient as they navigate their treatment with LISRAYA.

Cost Assistance

Eligible patients with private insurance may pay as little as $0* through the My Compass Support Copay Savings Program

The PAL can also help your Medicare, Medicaid and Government Insurance patients identify organizations that may be able to provide cost assistance.

My Compass Support Bridge Program

We are committed to ensuring that any delays in coverage won't impact your patient's care. If a LISRAYA authorization for your patient is initially denied and an appeal is submitted, your patient may qualify to receive medication at no cost while their appeal is pending to ensure they can begin treatment quickly.

Specialty Pharmacy Coordination

The PAL works directly with your patient's specialty pharmacy to ensure seamless prescription processing, responsive patient support, and on-time shipments of LISRAYA directly to your patient's home.

***Terms & Conditions**

The My Compass Support Copay Savings Program is available to eligible private insured patients only and is subject to the terms and conditions, including but not limited to the following:

- Not valid for patients whose prescriptions are reimbursed in whole or in part by any government-funded program (including Medicare, Medicaid, VA, TRICARE, or similar programs)
- Patient must be prescribed LISRAYA™ (brepocitinib) for an FDA-approved indication
- Patient must be a resident of the United States
- Patient must have commercial insurance coverage and an out-of-pocket cost for LISRAYA

Additional restrictions apply. My Compass Support reserves the right to modify or discontinue the program at any time without notice. This program is not insurance and is not intended to substitute for insurance.

Important Safety Information (continued)

Avoid use of LISRAYA in patients with an active, serious infection, including localized infections. Consider the risks and benefits of LISRAYA in patients with chronic or recurrent infection prior to initiating treatment. Closely monitor patients for signs and symptoms of infection during and after treatment with LISRAYA. If a serious infection occurs, interrupt LISRAYA treatment until the infection resolves or is adequately treated.

my compass support

End-to-End Support for Your Practice

Once your patient is enrolled in My Compass Support, their PAL will support you and your team by facilitating the authorization process.

Access Toolkit

The PAL will provide an Access Toolkit with:

A summary of benefits

Relevant payer forms and authorization requirements

A customizable Statement of Medical Necessity template

Submission Support & Monitoring

The PAL is available to answer any submission-related questions that you and your team may have. The clinical teams at our specialty pharmacy partners can also provide additional support in preparing your patient's authorization submission.

The PAL will track the authorization request and keep you updated throughout the process.

Important Safety Information (continued)

Mortality. A higher rate of all-cause mortality, including sudden cardiovascular death, was observed with another Janus kinase (JAK) inhibitor when compared to tumor necrosis factor (TNF) blockers in patients with rheumatoid arthritis (RA) 50 years of age and older with at least one cardiovascular risk factor. LISRAYA is not approved for use in patients with RA.

Malignancy. Malignancies have occurred in patients treated with LISRAYA. A higher rate of malignancies (excluding non-melanoma skin cancer), lymphomas, and lung cancers was observed with another JAK inhibitor when compared to TNF blockers in patients with RA.

LISRAYA™ (brepocitinib)

How to Enroll Your Patients

There are three ways to enroll your patients in My Compass Support for LISRAYA:

Submit a combined Prescription and My Compass Support Enrollment form on **MyCompassSupport.com**

Scan the code to access and submit the forms from your phone

Download the forms from the website and fax the completed documents to **1-844-341-0485** or email to **mcs@priovant.com**

Alternatively, you can e-prescribe LISRAYA and the specialty pharmacy will contact your patient directly to enroll in My Compass Support.

We're Here to Help

For dedicated support, contact us at:
Phone: 1-888-736-9788
Email: mcs@priovant.com
Website: MyCompassSupport.com

Important Safety Information (continued)

LISRAYA is not approved for use in patients with RA. Patients who are current or past smokers are at additional increased risk.

Major Adverse Cardiovascular Events (MACE). Major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) have occurred in patients treated with LISRAYA.

my compass support

Important Safety Information and Indication and Usage

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS

Indications and Usage

LISRAYA (brepocitinib) is indicated for the treatment of adults with dermatomyositis (DM).

Limitations of Use

Not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.

Warnings and Precautions:

Serious infections. Patients treated with LISRAYA are at increased risk of developing serious bacterial, fungal, viral, and opportunistic infections that may lead to hospitalization or death. Reported infections with use of Janus kinase (JAK) inhibitors, including LISRAYA:

- Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Evaluate and test patients for latent and active TB infection prior to and during LISRAYA treatment. If positive, treat for TB. Monitor all patients for active TB during treatment including patients who tested negative for a latent TB infection prior to LISRAYA treatment.
- Invasive fungal infections. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
- Bacterial, viral (including herpes zoster), and other infections due to opportunistic pathogens.

Avoid use of LISRAYA in patients with an active, serious infection, including localized infections. Consider the risks and benefits of LISRAYA in patients with chronic or recurrent infection prior to initiating treatment. Closely monitor patients for signs and symptoms of infection during and after treatment with LISRAYA. If a serious infection occurs, interrupt LISRAYA treatment until the infection resolves or is adequately treated.

Mortality. A higher rate of all-cause mortality, including sudden cardiovascular death, was observed with another Janus kinase (JAK) inhibitor when compared to tumor necrosis factor (TNF) blockers in patients with rheumatoid arthritis (RA) 50 years of age and older with at least one cardiovascular risk factor. LISRAYA is not approved for use in patients with RA.

Malignancy. Malignancies have occurred in patients treated with LISRAYA. A higher rate of malignancies (excluding non-melanoma skin cancer), lymphomas, and lung cancers was observed with another JAK inhibitor when compared to TNF blockers in patients with RA. LISRAYA is not approved for use in patients with RA. Patients who are current or past smokers are at additional increased risk.

Major Adverse Cardiovascular Events (MACE). Major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) have occurred in patients treated with LISRAYA. A higher rate of MACE was observed with another JAK inhibitor when compared to TNF blockers in patients with RA 50 years of age and older with at least one cardiovascular risk factor. LISRAYA is not approved for use in patients with RA. Patients who are current or past smokers are at additional increased risk. Discontinue LISRAYA in patients who have experienced a myocardial infarction or stroke.

Thrombosis. Thromboses, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated for inflammatory conditions with JAK inhibitors, including LISRAYA. Many of these adverse reactions were serious and some resulted in death.

A higher rate of thromboses was observed with another JAK inhibitor when compared to TNF blockers in patients with RA 50 years of age and older with at least one cardiovascular risk factor. LISRAYA is not approved for use in patients with RA. Avoid LISRAYA in patients who may be at risk of thrombosis. If symptoms of thrombosis occur, discontinue LISRAYA, promptly evaluate, and appropriately treat.

Hypersensitivity. LISRAYA is contraindicated in patients with known hypersensitivity to brepocitinib or any of its excipients. Hypersensitivity reactions were reported in patients receiving LISRAYA. Some events were serious.

Gastrointestinal Perforations. Gastrointestinal perforation has been reported in patients treated with JAK inhibitors, including LISRAYA. Monitor LISRAYA-treated patients who may be at risk for gastrointestinal perforation.

Hypoglycemia in Patients with Diabetes. LISRAYA may cause hypoglycemia in patients with diabetes. Hypoglycemia, including severe hypoglycemia, has been reported following initiation of JAK inhibitors in patients with diabetes. During treatment with LISRAYA, consider increased monitoring of blood glucose as clinically indicated in patients with diabetes.

Laboratory Abnormalities. LISRAYA has been associated with lab abnormalities including neutropenia, lymphopenia, anemia, increases in lipid parameters, and liver enzyme elevations.

Immunizations. Avoid use of live vaccines during or immediately prior to LISRAYA therapy initiation. Prior to initiating LISRAYA treatment, update immunizations, including prophylactic varicella zoster or herpes zoster vaccinations, according to current immunization guidelines.

Embryofetal Toxicity. Based on findings in animal studies, LISRAYA may cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to starting treatment. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LISRAYA and for 3 days following the last dose.

Adverse Reactions

The most common adverse reactions occurring in ≥5% of DM subjects and ≥2% greater than placebo were upper respiratory tract infection, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, fall, influenza, and acne.

Special Populations

Pregnancy. Based on findings in animal studies, LISRAYA may cause fetal harm when administered to a pregnant woman. Available data from LISRAYA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

Lactation. There are no data on the presence of brepocitinib in human milk, the effects on the breastfed infant, or the effects on milk production.

Hepatic Impairment. LISRAYA is not recommended in patients with severe hepatic impairment.

Renal Impairment. LISRAYA is not recommended in patients with severe renal impairment.

Please see the Full Prescribing Information, including BOXED WARNING, and Medication Guide.

My Compass Support for LISRAYA

Helping patients enroll is easy:

- **Submit** a combined Prescription and My Compass Support Enrollment form on **MyCompassSupport.com**

or

- **Scan** the code to access and submit the forms from your phone

or

- **Download** the forms from the website and fax the completed documents to **1-844-341-0485** or email to **mcs@priovant.com**

Contact Us Anytime

Phone: 1-888-736-9788
Email: mcs@priovant.com

my compass support

priovant therapeutics

LIS-139 08/26